Roche Holding (RHHBY)
(Delayed Data from OTC)
$30.25 USD
+0.23 (0.77%)
Updated Apr 26, 2024 04:00 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
RHHBY 30.25 +0.23(0.77%)
Will RHHBY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RHHBY
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Other News for RHHBY
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
AbbVie's Q1: Positive Surprise
Roche price target lowered by CHF 10 at UBS
Roche price target lowered by CHF 20 at Barclays
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)